【摘要】 目的评价国际大样本数据库子宫内膜癌的临床诊治和预后因素分析。方法选取1995年6月—2013年12月国际TCGA组织诊断治疗的子宫内膜癌患者连续病例,分析临床诊疗的特征,评价临床客观疗效和生存时间。结合lncRNA RP11-350N15.6基因的表达和相关性分析,评价患者的预后指标。结果共497例子宫内膜癌入选。71.6%的患者为Ⅰ~Ⅱ期,白种人为72.6%,子宫内膜腺癌为75.9%,81.1%患者为绝经后患者。RP11-350N15.6基因表达与肿瘤组织病理和分级以及7个重要的肿瘤驱动基因具有明显相关性,高表达组总生存时间明显延长。结论国际TCGA子宫内膜癌研究的诊断治疗符合临床规范,高表达RP11-350N15.6是患者具有良好预后的重要指标。更多还原

【Abstract】 Objective To evaluate the clinical diagnosis,treatment and prognostic factors of endometrial cancer in international sample database. Methods From June 1995 to December 2013,consecutive patients with endometrial cancer diagnosed and treated in TCGA organizations were enrolled. Clinical characteristics,objective response and survival time were evaluated,and correlation analysis with lncRNA RP11-350N15. 6 gene was performed. Results A total of 497 patients with endometrial carcinoma were enrolled,and 71. 6% of the patients were in stage Ⅰ ~ Ⅱ,race of 72. 6%patients was white,75. 9% patients were endometrial adenocarcinoma and 81. 1% patients were postmenopausal patients. Significant correlation was found between RP11-350N15. 6 expression and pathological / grade /7 important driver genes,and patients with RP11-350N15. 6 over-expression had longer overall survival time. Conclusion Diagnosis and treatment of the International TCGA endometrial cancer research meets clinical guidelines. RP11-350N15. 6 over-expression is an important indicator of the patients with good prognosis.更多还原